Watch our video: Outcomes for Rheumatic Disease Patients with COVID-19: Dr Kathryn Dao ( @KDAO2011) discusses plenary abstract #0430 presented Friday at the #ACR20 annual meeting. https://t.co/QgD90Ea4Ft https://t.co/tQiwmxjayK

• https://bit.ly/3kbjX43

Pfizer vaccine data potentially shows >90% effectiveness via ⁦@nytimes⁩ https://t.co/jwVkmbMaTL

• https://www.nytimes.com/2020/11/09/health/covid-vaccine-pfizer.html?referringSo…

About half (51%) of patients from the FORWARD registry in the US had at least one telehealth appointment during COVID-19 pandemic and most were satisfied with the appointment @RheumNow #ACR20 Abstr#1962 https://t.co/z38ilD1n8Q

Summary of #ACR20 part A: - HCQ is not a problem in rheumatic dz pts in terms of causing QTc prolongation - Anti-phospholipid ab are found in a majority of hospitalized COVID19 pts — the most prevalent of which were anti-PST abs that are not in the of criteria for APS @rheumnow

What was the effect of COVID-19 in axSpA patients? From @rheum_cat In the early phase of COVID-19 there was a higher levels of stress and anxiety leading to higher BASDAI scores @RheumNow #ACR20 Abstr#1884

Tocilizumab NOT effective in preventing mechanical ventilation or death in moderately ill COVID-19 pts. Double-blind, Placebo, RCT (n=243) @RheumNow #ACR20 Abs#L07 #ACRbest https://t.co/juSQRCnTeD

Does IL-6 blockade prevent mechanical ventilation or death in #COVID19? MGH study by Dr. Stone Abst#L07 graph shows no benefit @RheumNow #ACR20 https://t.co/DHfHYJCkod